Elon Musk has praised it too
Semaglutide (Wegovy) In the pivotal STEP-1 trial, semaglutide 2.4 mg produced ~14.9% total body weight loss , significantly greater than placebo5
But, in compliance with FDA rules, compounders can still make alternative versions of the drugs if they modify doses, add other ingredients or change the method of giving the treatment to meet a specific patient's needs
Clinicians should monitor patients for common adverse effects, including nausea, diarrhea, vomiting, constipation, and abdominal pain
One part of the brain affected by GLP-1 is the hypothalamus
Compounding pharmacies offer the advantage of customized dosages and formulations, ensuring a personalized approach to weight loss treatment